$46.00
-0.79 (-1.69%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PLSE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 6 with posted results
Held by 6 tracked-famous managers (Balyasny Asset Management L.P., CITADEL ADVISORS LLC, Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, +1 more) · FINRA short interest 7.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial FibrillationNCT06959121Freedom from atrial fibrillation/atrial flutter/atrial tachycardiaOpen-label · Treatment | Not applicable | Recruiting | Device: CellFX® nsPFA™ Cardiac Surgery System | Atrial Fibrillation, Maze Procedure, AF, Ablation | 135 | Apr 2027 | ≤ 254 d | 2026-01-12 |
| CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial FibrillationNCT06355063Rate of acute major adverse events (MAEs)Open-label · Treatment | Not applicable | Recruiting | Device: CellFX® nsPFA™ Cardiac Surgery System | Atrial Fibrillation, Surgery, Ablation of Atrial Fibrillation, Clamp Study | 30 | 2026-12-31 | in 134 d | 2026-01-12 |
| NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX SystemNCT07018596Proportion of participants with freedom from primary safety endpointOpen-label · Treatment | Not applicable | Recruiting | Device: CellFX nsPFA Cardiac Catheter System | Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia | 215 | Oct 2026 | ≤ 73 d | 2026-05-06 |
| Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode SystemNCT07287176Volume Reduction Ratio (VRR)Open-label · Treatment | Not applicable | Recruiting | Device: nPulse Vybrance Percutaneous Electrode System | Thyroid Nodule, Thyroid Goiter, Ablation | 100 | 2026-06-30 | — | 2026-04-15 |
| CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial FibrillationNCT06696170Rate of primary safety major adverse events (MAEs)Open-label · Treatment | Not applicable | Recruiting | Device: CellFX nano-pFA 360 Endocardial Ablation Catheter System | Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia | 60 | 2026-06-25 | — | 2026-05-05 |
| CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid NodulesNCT06117085Number of Participants with serious adverse device effectsOpen-label · Treatment | Not applicable | Completed | Device: CellFX® Percutaneous Electrode (PE) System | Thyroid Nodule (Benign) | 30 | 2024-11-18actual | — | 2024-11-21 |
| CellFX Treat & Resect Low-Risk BCC Feasibility StudyNCT04918381results2022-12-14Number of Lesions With BCC Histological ClearanceOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: CellFX System | BCC - Basal Cell Carcinoma, BCC, Excision Margin | 30 | 2022-03-02actual | — | 2023-01-11 |
| CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common WartsNCT04738734results2023-11-21Percentage of Warts ResolvedRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer | Warts, Warts Hand, Verruca | 150 | 2021-12-15actual | — | 2023-11-24 |
| Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) LesionsNCT04539886results2024-04-25Percentage of Lesions With Improvement as Assessed With the Global Aesthetic Improvement Scale (GAIS)Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: CellFX System, Intralesional Electrodesiccation | Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia | 60 | 2021-02-02actual | — | 2024-04-25 |
| Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization StudyNCT04249115Clearance Rate of SK LesionsOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Study enrollment was halted due to a business decision by the Sponsor to focus resources on other clinical areas outside of dermatology. | Device: Nano-Pulse Stimulation (NPS) | Lesion Skin, Seborrheic Keratosis, Skin Lesion, Benign Skin Tumor | 175 | 2020-08-13actual | — | 2023-10-30 |
| CellFX System for the Treatment of Cutaneous Non-Genital WartsNCT04554394results2023-07-27Percentage of Verrucae ClearedRandomized · Open-label · TreatmentStudy Protocol ↗ | Not applicable | Completed | Device: CellFX Device | Warts, Warts Hand, Verruca | 62 | 2020-06-09actual | — | 2023-07-27 |
| Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization StudyNCT04253418SH Lesion Clearance RateOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Study enrollment was halted due to a business decision by the Sponsor to focus resources on other clinical areas outside of dermatology. | Device: Nano-Pulse Stimulation (NPS) | Sebaceous Hyperplasia, Skin Abnormalities, Skin Lesion | 125 | 2020-05-14actual | — | 2023-10-30 |
| Nano-Pulse Stimulation (NPS) in Sebaceous HyperplasiaNCT03612570results2024-04-12Total Number of Cleared SH LesionsOpen-label · TreatmentStudy Protocol ↗ | Not applicable | Completed | Device: Nano-Pulse Stimulation Device | Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia | 72 | 2018-09-05actual | — | 2024-04-12 |
| Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis StudyNCT03846531results2023-08-22Clearance of SK LesionsNon-randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Nano-Pulse Stimulation (NPS) | Lesion Skin, Seborrheic Keratosis | 58 | 2017-11-13actual | — | 2023-08-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19